Glenmark Pharmaceuticals on Friday (September 5, 2025) mentioned it has initiated a multi-country Phase 3 clinical trial for Envafolimab, a novel drug for third-stage non-small cell lung cancer.
The firm mentioned it has obtained approval from the Drugs Controller General of India to start affected person enrolment and dosing within the nation.
In parallel, the drug agency has submitted a clinical trial software in Russia and is getting ready to open further clinical trial websites in Brazil and Mexico, Glenmark mentioned in a press release.
The randomised, multi-centre, Phase 3 trial will assess the efficacy, security, pharmacokinetics, and immunogenicity of Envafolimab in sufferers with third-stage non-small cell lung cancer (NSCLC).
Lung cancer stays the main explanation for cancer-related deaths worldwide, with NSCLC comprising round 80-85% of circumstances.
“By advancing this trial across multiple geographies, we are reinforcing our commitment to transforming the standard of care in Stage III NSCLC and addressing one of the greatest unmet needs in cancer treatment today,” Glenmark Pharmaceuticals Global Head of Clinical Development Monika Tandon mentioned.
Shares of Glenmark settled 3.3% up at ₹2,056.35 apiece on the BSE.
